Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028

Keros Therapeutics, Inc.

2025-Q3 EPS reported $2.68 vs consensus -$1.07 ▲ beat (+351.0%)

Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.
R&D expenses fell to $19.5M from $49.2M after elritercept transition to Takeda.
Cash and equivalents $693.5M; board authorized $375M return to stockholders.
Takeda plans to initiate Phase 3 trial of elritercept in first-line myelodysplastic syndromes.
Keros expects to fund operations into H1 2028 after capital return.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.